Interleukin-1 receptor antagonist enhances chemosensitivity to fluorouracil in treatment of Kras mutant colon cancer

Figure 7 Interleukin-1RA enhances the chemosensitivity to fluorouracil and delays the survival time of tumor-bearing nude mice. A and B: The tumor size of the control group treated with PBS (100 μL/mouse) for 3 wk significantly increased compared to that in the fluorouracil (5-FU) group and the 5-FU and interleukin (IL)-1RA group (dose per nude mouse: 20 mg/kg of 5-FU; 1.5 mg of IL-1RA); C: The tumor weights (g) of the nude mice in the 5-FU and IL-1RA group were decreased compared with those in the 5-FU group (5-FU group vs Ctrl: ^aP < 0.0001; 5-FU and IL-1RA group vs 5-FU group: ^bP = 0.0006; comparison of multiple groups: P < 0.0001); D: The tumor volumes (cm³) of nude mice in the 5-FU and IL-1RA group were decreased compared with those in the 5-FU group and the control group (18^th day: 5-FU and IL-1RA group vs Ctrl: P = 0.0007; 5-FU and IL-1RA group vs 5-FU group: P = 0.0192; comparison of multiple groups: P = 0.0001); E: The tumor diameter (cm) of the nude mice in the 5-FU and IL-1RA group was decreased compared with that in the 5-FU group and the control group (18^th day: t5-FU and IL-1RA group vs Ctrl: P < 0.0001; 5-FU and IL-1RA group vs 5-FU group: P = 0.0086; comparison of multiple groups: P < 0.0001); F: The survival time (d) of nude mice with xenograft tumors treated with 5-FU and IL-1RA was significantly longer than that of the nude mice with tumors treated with 5-FU (log-rank test, P = 0.0008; 5-FU and IL-1RA group vs 5-FU group: P = 0.0413).